A clinical primer for the expected and potential post-COVID-19 syndromes
Joseph Varon, MD, FACP, FCCP, FCCM, FRSM

With 30 million infections already documented Worldwide and the potential to infect over a 100 million people, the long-term consequences of COVID-19 infections will be a major health care focus for years after the contagion subsides. The common complications are expected to be accompanied by familiar patterns of pain and aversive sensations.
Acute COVID-19 infections resemble other viral respiratory tract infections, presenting with fever, fatigue, dry cough, myalgias, and dyspnea .
Headaches, sore throat, rhinorrhea, gastrointestinal, gustation are also commonly reported presenting features.
COVID-19 penetrates human cells through its exquisite specificity to the angiotensin-converting enzyme-2 receptor.
The angiotensin-converting enzyme-2 receptor is widely expressed in human tissue, most notably in lung alveolar cells, small intestine enterocytes, and the vascular endothelium
The complications of COVID are most often related to overexuberant immunological responses to the viral infection in the tissues or protective membranes of affected organs. The most severe damage seems to be a consequence of substantial monocyte and macrophage recruitment into affected tissues and their unchecked activation.
Visceral thrombosis represents a second mechanism in which COVID-19 can create complications. Microthrombi during COVID-19 infections have been documented to occur in nearly every organ. Dramatically elevated levels of D-dimer and fibrin degradation products are a hallmark of the coagulopathy